AU
UK
CA
NZ
IND
US
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has entered a strategic partnership with InvestorHub, a direct-to-investor engagement software provider, as part of a broader effort to streamline communications with shareholders and the investment community. The agreement establishes an interactive investor hub designed to consolidate corporate …
Evoke Pharma announced a set of distribution agreements intended to materially broaden patient access to GIMOTI® nasal spray, the only FDA-approved intranasal treatment for adults with acute and recurrent diabetic gastroparesis. The company said strategic arrangements with Omnicell (NASDAQ: OMCL) and Brentwood Pharmacy will …
Marker Therapeutics reported encouraging early efficacy and tolerability data from its Phase 1 APOLLO study of MT-601, a Multi-Antigen Recognizing T cell product, in relapsed lymphoma. The trial enrolled 24 B-cell lymphoma patients across seven U.S. clinical sites with dose levels spanning 100×10^6 to …
Serina Therapeutics (NYSE American: SER) said the U.S. Food and Drug Administration gave constructive feedback that supports advancing SER-252, a POZ-enabled apomorphine formulation aimed at treating advanced Parkinson’s disease, via a 505(b)(2) NDA pathway. The company plans to launch a registrational clinical development program …
Eisai Co., Ltd. and Biogen Inc. announced the first European launches of LEQEMBI® (lecanemab) in Austria on August 25, 2025, with Germany to follow on September 1, 2025 — the initial rollout following the European Commission’s marketing authorisation in April 2025. These are the …
argenx reported positive topline results from the Phase 3 ADAPT SERON study evaluating VYVGART® (efgartigimod) in patients with AChR-Ab seronegative generalized myasthenia gravis (gMG). The trial achieved its primary endpoint, with a reported p-value of 0.0068 for improvement on the Myasthenia Gravis Activities of …
Alvotech (NASDAQ: ALVO) and Advanz Pharma Holdco Limited said the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept). The approval is a centralized marketing authorisation that covers all European Economic Area (EEA) countries — the 27 EU member states plus Norway, …
Smith & Nephew plc (NYSE: SNN) received a price target increase from Canaccord Genuity Group, moving to USD 36 from USD 28 while maintaining a Hold rating, according to a recent research note. The revision follows a period of reassessment across the sell-side: HSBC …
Alcon reported second-quarter 2025 results with net sales of approximately $2.6 billion, a 4% increase on a reported basis and 3% in constant currency versus the prior-year quarter. The company posted diluted earnings per share of $0.35 and core diluted EPS of $0.76 for …
ICU Medical (NASDAQ: ICUI) was upgraded tooverweightby Piper Sandler in a Friday report, with aUSD145price target that indicates an estimated17.92%upside from recent levels, according to MarketBeat. The change reflects a more favorable stance on the company’s near-term risk-reward and earnings trajectory within medical supplies …
Please wait processing your request...